162 related articles for article (PubMed ID: 25545760)
1. Technical decision-making with higher order structure data: specific binding of a nonionic detergent perturbs higher order structure of a therapeutic monoclonal antibody.
Budyak IL; Doyle BL; Weiss WF
J Pharm Sci; 2015 Apr; 104(4):1543-7. PubMed ID: 25545760
[TBL] [Abstract][Full Text] [Related]
2. Technical decision making with higher order structure data: impact of a formulation change on the higher order structure and stability of a mAb.
Gruia F; Du J; Santacroce PV; Remmele RL; Bee JS
J Pharm Sci; 2015 Apr; 104(4):1539-42. PubMed ID: 25270279
[TBL] [Abstract][Full Text] [Related]
3. Technical decision making with higher order structure data: higher order structure characterization during protein therapeutic candidate screening.
Jiang Y; Li C; Li J; Gabrielson JP; Wen J
J Pharm Sci; 2015 Apr; 104(4):1533-8. PubMed ID: 25716705
[TBL] [Abstract][Full Text] [Related]
4. Technical decision making with higher order structure data: utilization of differential scanning calorimetry to elucidate critical protein structural changes resulting from oxidation.
Arthur KK; Dinh N; Gabrielson JP
J Pharm Sci; 2015 Apr; 104(4):1548-54. PubMed ID: 25561411
[TBL] [Abstract][Full Text] [Related]
5. Technical Decision Making With Higher Order Structure Data: Perspectives on Higher Order Structure Characterization From the Biopharmaceutical Industry.
Weiss WF; Gabrielson JP; Al-Azzam W; Chen G; Davis DL; Das TK; Hayes DB; Houde D; Singh SK
J Pharm Sci; 2016 Dec; 105(12):3465-3470. PubMed ID: 27743675
[TBL] [Abstract][Full Text] [Related]
6. Technical decision-making with higher order structure data: starting a new dialogue.
Gabrielson JP; Weiss WF
J Pharm Sci; 2015 Apr; 104(4):1240-5. PubMed ID: 25711138
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Characterization of Relationship Between Higher-Order Structure and FcRn Binding Affinity of Stress-Exposed Monoclonal Antibodies.
Tsuchida D; Yamazaki K; Akashi S
Pharm Res; 2016 Apr; 33(4):994-1002. PubMed ID: 26694753
[TBL] [Abstract][Full Text] [Related]
8. Membrane protein stability can be compromised by detergent interactions with the extramembranous soluble domains.
Yang Z; Wang C; Zhou Q; An J; Hildebrandt E; Aleksandrov LA; Kappes JC; DeLucas LJ; Riordan JR; Urbatsch IL; Hunt JF; Brouillette CG
Protein Sci; 2014 Jun; 23(6):769-89. PubMed ID: 24652590
[TBL] [Abstract][Full Text] [Related]
9. A Comparison Between Emerging and Current Biophysical Methods for the Assessment of Higher-Order Structure of Biopharmaceuticals.
Wen J; Batabyal D; Knutson N; Lord H; Wikström M
J Pharm Sci; 2020 Jan; 109(1):247-253. PubMed ID: 31669605
[TBL] [Abstract][Full Text] [Related]
10. Aggregates in monoclonal antibody manufacturing processes.
Vázquez-Rey M; Lang DA
Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
[TBL] [Abstract][Full Text] [Related]
11. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
[TBL] [Abstract][Full Text] [Related]
12. Probing Thermal Stability of Proteins with Temperature Scanning Viscometer.
Jiang B; Jain A; Lu Y; Hoag SW
Mol Pharm; 2019 Aug; 16(8):3687-3693. PubMed ID: 31306023
[TBL] [Abstract][Full Text] [Related]
13. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
Goldberg DS; Bishop SM; Shah AU; Sathish HA
J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
[TBL] [Abstract][Full Text] [Related]
14. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
Brummitt RK; Nesta DP; Roberts CJ
J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
[TBL] [Abstract][Full Text] [Related]
15. Use of the 2D
Hwang TL; Batabyal D; Knutson N; Wikström M
Molecules; 2021 May; 26(9):. PubMed ID: 34063095
[TBL] [Abstract][Full Text] [Related]
16. Toward aggregation-resistant antibodies by design.
Lee CC; Perchiacca JM; Tessier PM
Trends Biotechnol; 2013 Nov; 31(11):612-20. PubMed ID: 23932102
[TBL] [Abstract][Full Text] [Related]
17. A critical evaluation of self-interaction chromatography as a predictive tool for the assessment of protein-protein interactions in protein formulation development: a case study of a therapeutic monoclonal antibody.
Le Brun V; Friess W; Bassarab S; Mühlau S; Garidel P
Eur J Pharm Biopharm; 2010 May; 75(1):16-25. PubMed ID: 20102739
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches.
Li M; Beaumont VA; Akbar S; Duncan H; Creasy A; Wang W; Sackett K; Marzilli L; Rouse JC; Kim HY
MAbs; 2024; 16(1):2292688. PubMed ID: 38117548
[TBL] [Abstract][Full Text] [Related]
19. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective.
Rester U
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):559-68. PubMed ID: 18600572
[TBL] [Abstract][Full Text] [Related]
20. Orthogonal Methods for Characterizing the Unfolding of Therapeutic Monoclonal Antibodies: Differential Scanning Calorimetry, Isothermal Chemical Denaturation, and Intrinsic Fluorescence with Concomitant Static Light Scattering.
Temel DB; Landsman P; Brader ML
Methods Enzymol; 2016; 567():359-89. PubMed ID: 26794361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
